Anterix (ATEX) Cash & Equivalents (2013 - 2025)

Anterix has reported Cash & Equivalents for 13 years, with the latest figure at $29.5 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 2.56% year-over-year to $29.5 million; the trailing twelve-month figure through Dec 2025 stood at $29.5 million (up 2.56% YoY), and the FY2025 full-year result was $47.4 million, down 21.8% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $29.5 million, down from $39.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $127.8 million in Q4 2021, with the low at $28.8 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $64.9 million across 5 years, with a median of $54.6 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 66.42% — and 2024, when it jumped 78.12%.
• Anterix's Cash & Equivalents stood at $127.8 million in 2021, then plunged by 54.99% to $57.5 million in 2022, then climbed by 7.86% to $62.0 million in 2023, then plunged by 53.58% to $28.8 million in 2024, then advanced by 2.56% to $29.5 million in 2025.
• The last three Cash & Equivalents figures came in at $29.5 million (Q4 2025), $39.1 million (Q3 2025), and $41.4 million (Q2 2025), per Business Quant data.